AP2S1 and ovarian carcinoma: In the current work we have shown the feasibility of conjugating a small molecule SMAC mimetic to a sigma-2 ligand and demonstrated the effectiveness of the conjugate in treatment of ovarian cancer using in vitro and in vivo studies.